{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:09:18Z","timestamp":1786975758400,"version":"build-2736575974"},"reference-count":56,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Use of the US Food and Drug Administration\u2019s Accelerated Approval pathway assumes that patients are willing to accept uncertainty about clinical benefit in exchange for faster access to new cancer drugs. However, little is known about how patients view this trade-off or the circumstances under which they consider it acceptable.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To explore patients\u2019 views on the trade-off between faster approval and evidentiary certainty regarding the clinical benefit of new cancer drugs in the US.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This qualitative study used semistructured interviews conducted online between January 27 and April 1, 2025, with patients aged 18 years or older diagnosed with breast cancer. Purposive sampling was used to achieve maximum variation in cancer stage, treatment status, age, and sociodemographic background.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was patients\u2019 views on the trade-off between faster drug approval and evidentiary certainty. Interview transcripts were thematically analyzed to identify key patterns in understanding, experiences of uncertainty, attitudes toward waiting, treatment priorities, and views on regulatory decision-making.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 125 individuals registered their interest and met eligibility criteria to participate. After purposive sampling, 30 participated in this study (10 aged 20-39 years [33.3%], 12 aged 40-59 years [40.0%], and 8 aged &amp;gt;60 years [26.7%]; all female), representing 17 US states (9 Northeast, 12 Midwest, 4 South, 5 West). A total of 13 participants (43.3%) had metastatic disease, 21 (70.0%) were receiving active treatment, and 27 (90.0%) had received at least 1 systemic therapy. Faster approval at the expense of certainty about the clinical benefit of new cancer drugs was considered most acceptable when no alternative treatments existed or when the anticipated benefits were transformative. When clinical benefit was uncertain, participants emphasized the importance of survival and quality of life as priority treatment outcomes, the added risks of adverse effects, and the burden of intensive treatment. Many viewed broader access to clinical trials, rather than faster regulatory approval, as an effective way to address unmet needs while facilitating evidence generation for approval.<\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance<\/jats:title>\n In this qualitative study of patients diagnosed with breast cancer, there was a mismatch between when patients considered trading evidentiary certainty for faster approval as acceptable and the conditions under which many new cancer drugs are approved by the Food and Drug Administration. To better align regulatory approvals with patient values, use of accelerated approval may be most appropriate for drugs that are likely to address genuine treatment gaps or offer meaningful improvements in clinical outcomes over existing alternatives.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.17450","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:30:20Z","timestamp":1781019020000},"page":"e2617450","source":"Crossref","is-referenced-by-count":1,"title":["Patient Perspectives on Approval Speed vs Evidentiary Certainty in US Cancer Drug Approvals"],"prefix":"10.1001","volume":"9","author":[{"given":"Robin","family":"Forrest","sequence":"first","affiliation":[{"name":"Department of Health Policy, London School of Economics and Political Science, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, Department of Oncology, Guy\u2019s and St Thomas\u2019 NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Tregear","sequence":"additional","affiliation":[{"name":"National Breast Cancer Coalition, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Wyne","sequence":"additional","affiliation":[{"name":"National Breast Cancer Coalition, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly Fernandez","family":"Lynch","sequence":"additional","affiliation":[{"name":"Department of Medical Ethics and Health Policy, The Perelman School of Medicine, Carey Law School, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita K.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Jackson","sequence":"additional","affiliation":[{"name":"Law School, London School of Economics and Political Science, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin","family":"Naci","sequence":"additional","affiliation":[{"name":"Department of Health Policy, London School of Economics and Political Science, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"5","key":"zoi260490r2","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/jamainternmed.2018.8351","article-title":"Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials.","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"8","key":"zoi260490r4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S1470-2045(23)00319-4","article-title":"Common sense oncology: outcomes that matter.","volume":"24","author":"Booth","year":"2023","journal-title":"Lancet Oncol"},{"issue":"16","key":"zoi260490r5","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1056\/NEJMp2208954","article-title":"The on- and off-ramps of oncology accelerated approval.","volume":"387","author":"Fashoyin-Aje","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi260490r7","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S1470-2045(24)00596-5","article-title":"Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment.","volume":"25","author":"Forrest","year":"2024","journal-title":"Lancet Oncol"},{"issue":"11","key":"zoi260490r10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi260490r11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions.","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"zoi260490r12","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s12282-024-01634-x","article-title":"Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price.","volume":"31","author":"Michaeli","year":"2024","journal-title":"Breast Cancer"},{"issue":"7","key":"zoi260490r13","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the clinical benefit of cancer drugs receiving accelerated approval.","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"17","key":"zoi260490r14","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jama.2024.2396","article-title":"Clinical benefit and regulatory outcomes of cancer drugs receiving accelerated approval.","volume":"331","author":"Liu","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"zoi260490r15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated Criteria for Reporting Qualitative Research (COREQ): a 32-item checklist for interviews and focus groups.","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"issue":"2","key":"zoi260490r16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology.","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"issue":"11","key":"zoi260490r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.47649","article-title":"Patient, caregiver, and clinician perspectives on the time burdens of cancer care.","volume":"7","author":"Gupta","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi260490r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.47924","article-title":"Health care contact days in older adults with metastatic cancer.","volume":"8","author":"Gupta","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi260490r19","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1200\/OP.22.00737","article-title":"Evaluating the time toxicity of cancer treatment in the CCTG CO.17 trial.","volume":"19","author":"Gupta","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"8","key":"zoi260490r20","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/jnci\/djae077","article-title":"The association of health-care contact days with physical function and survival in CCTG\/AGITG CO.17.","volume":"116","author":"Gupta","year":"2024","journal-title":"J Natl Cancer Inst"},{"issue":"35","key":"zoi260490r21","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1200\/JCO.22.00535","article-title":"Overall survival, progression-free survival, and tumor response benefit supporting initial US Food and Drug Administration approval and indication extension of new cancer drugs, 2003-2021.","volume":"40","author":"Michaeli","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi260490r22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(22)00200-5","article-title":"The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"16","key":"zoi260490r23","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1200\/JCO.22.01799","article-title":"Financial toxicity in cancer care: implications for clinical care and potential practice solutions.","volume":"41","author":"Khan","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi260490r24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.55388","article-title":"Financial toxicity among patients with breast cancer worldwide: a systematic review and meta-analysis.","volume":"6","author":"Ehsan","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"15","key":"zoi260490r25","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The time toxicity of cancer treatment.","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"issue":"17","key":"zoi260490r26","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1056\/NEJMoa1204410","article-title":"Patients\u2019 expectations about effects of chemotherapy for advanced cancer.","volume":"367","author":"Weeks","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi260490r27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0259815","article-title":"The role of health literacy in cancer care: a mixed studies systematic review.","volume":"16","author":"Holden","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"zoi260490r28","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkad010","article-title":"Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift.","volume":"7","author":"Hopkins","year":"2023","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"1","key":"zoi260490r30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12885-018-4164-5","article-title":"Cancer patients\u2019 knowledge about their disease and treatment before, during and after treatment: a prospective, longitudinal study.","volume":"18","author":"Berger","year":"2018","journal-title":"BMC Cancer"},{"issue":"8","key":"zoi260490r31","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1001\/jamainternmed.2018.3137","article-title":"Reviving the FDA\u2019s authority to publicly explain why new drug applications are approved or rejected.","volume":"178","author":"Herder","year":"2018","journal-title":"JAMA Intern Med"},{"key":"zoi260490r32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081720","article-title":"Patients deserve better information on new drugs.","volume":"387","author":"Davis","year":"2024","journal-title":"BMJ"},{"issue":"10439","key":"zoi260490r33","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(24)00747-5","article-title":"The Lancet Breast Cancer Commission.","volume":"403","author":"Coles","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"zoi260490r34","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1377\/hlthaff.2024.01134","article-title":"New cancer drug approvals: less than half of important clinical trial uncertainties reported by the FDA to clinicians, 2019-22.","volume":"44","author":"Cherla","year":"2025","journal-title":"Health Aff (Millwood)"},{"issue":"16","key":"zoi260490r35","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2025.13917","article-title":"Reporting of clinical trial uncertainties with new cancer drugs in journal publications and clinical guidelines.","volume":"334","author":"Cherla","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"zoi260490r36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1377\/hlthaff.2023.00466","article-title":"Physicians\u2019 perspectives on FDA regulation of drugs and medical devices: a national survey.","volume":"43","author":"Dhruva","year":"2024","journal-title":"Health Aff (Millwood)"},{"issue":"14","key":"zoi260490r37","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1001\/jama.2015.16984","article-title":"Physicians\u2019 knowledge about FDA approval standards and perceptions of the \u201cbreakthrough therapy\u201d designation.","volume":"315","author":"Kesselheim","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"zoi260490r38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/1073110520935352","article-title":"Facilitating both evidence and access: improving FDA\u2019s accelerated approval and expanded access pathways.","volume":"48","author":"Lynch","year":"2020","journal-title":"J Law Med Ethics"},{"issue":"4","key":"zoi260490r39","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3322\/caac.70006","article-title":"Cancer in rural America: improving access to clinical trials and quality of oncologic care.","volume":"75","author":"Unger","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"zoi260490r40","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2024.1690","article-title":"Geographic distribution of clinical trials for advanced-stage cancer.","volume":"10","author":"Swenson","year":"2024","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi260490r41","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1200\/OP.24.00261","article-title":"State of geographic access to cancer treatment trials in the United States: are studies located where patients live?","volume":"21","author":"Kirkwood","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"18","key":"zoi260490r42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2104846","article-title":"\u201cDangling\u201d accelerated approvals in oncology.","volume":"384","author":"Beaver","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi260490r43","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1200\/JCO.24.00892","article-title":"Redefining available therapy in oncology accelerated approval decisions.","volume":"43","author":"Patel","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi260490r44","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1001\/jamaoncol.2025.1002","article-title":"Overall survival and quality-of-life superiority in modern phase 3 oncology trials: a meta-epidemiological analysis.","volume":"11","author":"Sherry","year":"2025","journal-title":"JAMA Oncol"},{"issue":"4","key":"zoi260490r45","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.7110","article-title":"Breakthrough therapy cancer drugs and indications with FDA approval: development time, innovation, trials, clinical benefit, epidemiology, and price.","volume":"22","author":"Michaeli","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"zoi260490r46","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2026","article-title":"Factors in time to full approval or withdrawal for anticancer medicines granted accelerated approval by the FDA.","volume":"8","author":"Tibau","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi260490r47","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann Oncol"},{"key":"zoi260490r48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073242","article-title":"FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.","volume":"381","author":"Michaeli","year":"2023","journal-title":"BMJ"},{"issue":"12","key":"zoi260490r49","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/cncr.22719","article-title":"Use of health-related and cancer-specific support groups among adult cancer survivors.","volume":"109","author":"Owen","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"zoi260490r50","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/ecc.12122","article-title":"Participation in patient support groups among cancer survivors: do psychosocial and medical factors have an impact?","volume":"23","author":"Sautier","year":"2014","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"2","key":"zoi260490r51","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1080\/10705500801929601","article-title":"Determinants of participation in cancer support groups: the role of health beliefs.","volume":"15","author":"Sherman","year":"2008","journal-title":"Int J Behav Med"},{"key":"zoi260490r52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102113","article-title":"National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: a cross-sectional study.","volume":"91","author":"Etan","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"zoi260490r53","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer.","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi260490r54","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1093\/jnci\/djaf195","article-title":"Assessing outcomes emerging after conversion to regular approval for cancer drug indications granted accelerated approval, 1992-2021.","volume":"117","author":"Tibau","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"zoi260490r55","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103088","article-title":"Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study.","volume":"84","author":"Tibau","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"8","key":"zoi260490r56","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century.","volume":"22","author":"Scott","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"zoi260490r1","unstructured":"What we do. US Food and Drug Administration. 2024. Accessed November 10, 2025. https:\/\/www.fda.gov\/about-fda\/what-we-do"},{"key":"zoi260490r3","unstructured":"Expedited programs for serious conditions: drugs and biologics. US Food and Drug Administration. 2014. Accessed November 10, 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/expedited-programs-serious-conditions-drugs-and-biologics"},{"key":"zoi260490r6","unstructured":"Demonstrating substantial evidence of effectiveness for human drug and biological products. US Food and Drug Administration. 2019. Accessed November 10, 2025. https:\/\/www.fda.gov\/media\/133660\/download"},{"key":"zoi260490r8","unstructured":"Cancer stat facts: female breast cancer. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. 2025. Accessed November 10, 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html"},{"key":"zoi260490r9","unstructured":"Breast cancer statistics. American Cancer Society. 2025. Accessed November 10, 2025. https:\/\/cancerstatisticscenter.cancer.org\/types\/breast"},{"key":"zoi260490r29","unstructured":"Cancer facts & figures. American Cancer Society. 2025. Accessed November 10, 2025. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2025-cancer-facts-figures.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2850068\/forrest_2026_oi_260490_1780340755.47251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:30:28Z","timestamp":1781019028000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2850068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.17450","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]}}}